A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors

Trial Details

NCT ID
NCT06682988
Phase
PHASE2
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Mirvetuximab Soravtansine
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Edgewood, Kentucky, United States|39.01867,-84.58189
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Worcester, Massachusetts, United States|42.26259,-71.80229
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Both Cohorts
  • Participants with a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
  • Participants with platinum-resistant disease:
  • Participants with 1 prior line of platinum-based therapy who have received ≥ 4 cycles of platinum and had a response (complete response (CR) or par…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →